Marilesia Ferreira de Souza
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Marilesia Ferreira de Souza has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Ilce Mara de Syllos Cólus
Department of General Biology, State University of Londrina, Londrina 86057-970, PR, Brazil
6 shared publications - Mariana Bisarro dos Reis
Molecular Oncology Research Center Barretos Cancer Hospital Barretos Brazil
3 shared publications - Monyse de Nóbrega
Department of General Biology, Laboratory of Mutagenesis and Oncogenetics, Center of Biologic Sciences, State University of Londrina, Rodovia Celso Garcia Cid, PR-445, Km 380-University Campus, Londrina, PR, CEP 86057-970, Brazil
3 shared publications - Paulo Emílio Fuganti
Londrina Cancer Hospital
3 shared publications - Heloisa Lizotti Cilião
Department of General Biology, State University of Londrina, Londrina, Brazil
2 shared publications - Juliana Mara Serpeloni
State University of Londrina (UEL)
2 shared publications
Latest Publications
- Open Access
- 30 August 2026
- Published by MDPI AG in Non-Coding RNA
- Vol. 12 (5) , 33
Circulating Cell-Free miR-25-3p Is Upregulated in Brazilian Patients with Prostate Cancer and Contributes to Tumor Aggressiveness
Background/Objectives: Prostate cancer (PCa) has a high incidence worldwide, yet reliable prognostic biomarkers to distinguish indolent from aggressive forms are lacking. MicroRNAs (miRNAs), a class of small non-coding RNAs, are stable molecules that play an important role in cancer development and can be detected in circulation by non-invasive methods. This study aimed to examine the influence of the cell-free (cf) miRNAs levels on PCa risk and aggressiveness using plasma samples and cell models. Methods: Four overexpressed miRNAs in prostate cancer tissue were selected from The Cancer Genome Atlas database: miR-25-3p, miR-92a-1-5p, miR-92a-2-5p, and miR-148a-3p. Cf-miRNA levels were validated via quantitative reverse transcription polymerase chain reaction (RT-qPCR) in plasma samples from 80 PCa patients and 40 controls in a Brazilian cohort. Clinicopathological associations were analyzed to determine prognostic value. Subsequently, functional analyses were performed using transient transfection of miR-25-3p in the LNCaP cell line, assessing proliferation, migration, invasion, and target gene regulation. Results: Among the miRNAs analyzed, only miR-25-3p was upregulated in the plasma of PCa patients compared to controls (p = 0.013). Patients with International Society of Urological Pathology (ISUP) grade ≥2 presented higher expression levels of miR-25-3p (p = 0.020) compared to patients with ISUP grade 1. Overexpression of miR-25-3p significantly increased cell proliferation, colony formation, migration, and invasion capacity and modulated the expression of BCL2L11, CDH1, CDKN1C, EHZ2, and TP53 genes. Conclusions: miR-25-3p had an oncogenic role in PCa, showing a potential marker to assess PCa development and progression using liquid biopsy.
- 30 August 2026
- Published by MDPI AG in Non-Coding RNA
- Vol. 12 (5) , 33
Open AccessCirculating Cell-Free miR-25-3p Is Upregulated in Brazilian Patients with Prostate Cancer and Contributes to Tumor Aggressiveness
Background/Objectives: Prostate cancer (PCa) has a high incidence worldwide, yet reliable prognostic biomarkers to distinguish indolent from aggressive forms are lacking. MicroRNAs (miRNAs), a class of small non-coding RNAs, are stable molecules that play an important role in cancer development and can be detected in circulation by non-invasive methods. This study aimed to examine the influence of the cell-free (cf) miRNAs levels on PCa risk and aggressiveness using plasma samples and cell models. Methods: Four overexpressed miRNAs in prostate cancer tissue were selected from The Cancer Genome Atlas database: miR-25-3p, miR-92a-1-5p, miR-92a-2-5p, and miR-148a-3p. Cf-miRNA levels were validated via quantitative reverse transcription polymerase chain reaction (RT-qPCR) in plasma samples from 80 PCa patients and 40 controls in a Brazilian cohort. Clinicopathological associations were analyzed to determine prognostic value. Subsequently, functional analyses were performed using transient transfection of miR-25-3p in the LNCaP cell line, assessing proliferation, migration, invasion, and target gene regulation. Results: Among the miRNAs analyzed, only miR-25-3p was upregulated in the plasma of PCa patients compared to controls (p = 0.013). Patients with International Society of Urological Pathology (ISUP) grade ≥2 presented higher expression levels of miR-25-3p (p = 0.020) compared to patients with ISUP grade 1. Overexpression of miR-25-3p significantly increased cell proliferation, colony formation, migration, and invasion capacity and modulated the expression of BCL2L11, CDH1, CDKN1C, EHZ2, and TP53 genes. Conclusions: miR-25-3p had an oncogenic role in PCa, showing a potential marker to assess PCa development and progression using liquid biopsy.
- 4 August 2022
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 148 (10) , 2893-2910
The potential of cell-free and exosomal microRNAs as biomarkers in liquid biopsy in patients with prostate cancer
Purpose Prostate cancer (PCa) is the 4th most diagnosed cancer and the 8th leading cause of cancer-related death worldwide. Currently, clinical risk stratification models including factors like PSA levels, Gleason score, and digital rectal examination are used for this purpose. There is a need for novel biomarkers that can distinguish between indolent and aggressive pathology and reduce the risk of overdiagnosis/overtreatment. Liquid biopsy has a non-invasive character, can lead to less morbidity and provide new biomarkers, such as miRNAs, that regulate diverse important cellular processes. Here, we report an extended revision about the role of cell-free and exosomal miRNAs (exomiRNAs) as biomarkers for screening, diagnosis, prognosis, or treatment of PCa. Methods A comprehensive review of the published literature was conducted focusing on the usefulness, advantages, and clinical applications of cell-free and exomiRNAs in serum and plasma. Using PubMed database 53 articles published between 2012 and 2021 were selected and discussed from the perspective of their use as diagnostic, prognostic and therapeutic biomarkers for PCa. Results We identify 119 miRNAs associated with PCa development and the cell-free and exosomal miR-21, miR-141, miR-200c, and miR-375 were consistently associated with progression in multiple cohorts/studies. However, standardized experimental procedures, and well-defined and clinically relevant cohort studies are urgently needed to confirm the biomarker potential of cell-free and exomiRNAs in serum or plasma. Conclusion Cell-free and exomiRNAs in serum or plasma are promising tools for be used as non-invasive biomarkers for diagnostic, prognosis, therapy improvement and clinical outcome prediction in PCa patients.
- 4 August 2022
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 148 (10) , 2893-2910
The potential of cell-free and exosomal microRNAs as biomarkers in liquid biopsy in patients with prostate cancer
Purpose Prostate cancer (PCa) is the 4th most diagnosed cancer and the 8th leading cause of cancer-related death worldwide. Currently, clinical risk stratification models including factors like PSA levels, Gleason score, and digital rectal examination are used for this purpose. There is a need for novel biomarkers that can distinguish between indolent and aggressive pathology and reduce the risk of overdiagnosis/overtreatment. Liquid biopsy has a non-invasive character, can lead to less morbidity and provide new biomarkers, such as miRNAs, that regulate diverse important cellular processes. Here, we report an extended revision about the role of cell-free and exosomal miRNAs (exomiRNAs) as biomarkers for screening, diagnosis, prognosis, or treatment of PCa. Methods A comprehensive review of the published literature was conducted focusing on the usefulness, advantages, and clinical applications of cell-free and exomiRNAs in serum and plasma. Using PubMed database 53 articles published between 2012 and 2021 were selected and discussed from the perspective of their use as diagnostic, prognostic and therapeutic biomarkers for PCa. Results We identify 119 miRNAs associated with PCa development and the cell-free and exosomal miR-21, miR-141, miR-200c, and miR-375 were consistently associated with progression in multiple cohorts/studies. However, standardized experimental procedures, and well-defined and clinically relevant cohort studies are urgently needed to confirm the biomarker potential of cell-free and exomiRNAs in serum or plasma. Conclusion Cell-free and exomiRNAs in serum or plasma are promising tools for be used as non-invasive biomarkers for diagnostic, prognosis, therapy improvement and clinical outcome prediction in PCa patients.
- 16 June 2022
- Published by Springer Nature in Molecular Biology Reports
- Vol. 49 (9) , 9079-9087
Polymorphic variants of the CASP3, CASP9, BCL-2 and NKX3-1 genes as candidate markers for prostate cancer susceptibility and poor prognosis
Background There is an ongoing search for molecular markers that are specific, sensitive, and able to predict the stage of prostate cancer (PCa), which is the second most prevalent type of cancer in men worldwide. This study examined whether different single nucleotide polymorphisms (SNPs) were reliable markers of susceptibility to and prognosis of PCa in a sample of Brazilian patients. Methods and results DNA samples were extracted from peripheral blood cells of 283 PCa patients and matched with samples from healthy controls. Single nucleotide polymorphisms (SNPs in four genes (BCL-2–rs2279115, CASP3–rs4647603, CASP9–rs1052571, and NKX3-1–rs11781886) were genotyped by real-time PCR using the TaqMan® probe. Odds Ratios with 95% confidence intervals were calculated for allelic and genotypic frequencies. The association between polymorphic variants, risk of developing PCa, and clinicopathological characteristics was analyzed by univariate and multivariate logistic regression analysis. SNPs in CASP3, CASP9, and NKX3-1 genes, either alone or in combination (BCL-2+NKX3-1 and CASP3+NKX3-1) were associated with the risk of developing PCa. Genotypes and tumor histopathological data indicated that the BCL-2, NKX3-1, and CASP3 allelic variants, either alone or combined in pairs, were associated with a poor prognosis of PCa. Conclusions Genetic polymorphisms in CASP3, NKX3-1, and BCL-2 genes were associated with susceptibility to PCa. The SNPs in the three genes alone and the SNP in the BCL-2 gene combined with the other two genes were strongly associated with adverse outcomes in PCa patients and are promising candidates for molecular markers for PCa prognosis.
- 16 June 2022
- Published by Springer Nature in Molecular Biology Reports
- Vol. 49 (9) , 9079-9087
Polymorphic variants of the CASP3, CASP9, BCL-2 and NKX3-1 genes as candidate markers for prostate cancer susceptibility and poor prognosis
Background There is an ongoing search for molecular markers that are specific, sensitive, and able to predict the stage of prostate cancer (PCa), which is the second most prevalent type of cancer in men worldwide. This study examined whether different single nucleotide polymorphisms (SNPs) were reliable markers of susceptibility to and prognosis of PCa in a sample of Brazilian patients. Methods and results DNA samples were extracted from peripheral blood cells of 283 PCa patients and matched with samples from healthy controls. Single nucleotide polymorphisms (SNPs in four genes (BCL-2–rs2279115, CASP3–rs4647603, CASP9–rs1052571, and NKX3-1–rs11781886) were genotyped by real-time PCR using the TaqMan® probe. Odds Ratios with 95% confidence intervals were calculated for allelic and genotypic frequencies. The association between polymorphic variants, risk of developing PCa, and clinicopathological characteristics was analyzed by univariate and multivariate logistic regression analysis. SNPs in CASP3, CASP9, and NKX3-1 genes, either alone or in combination (BCL-2+NKX3-1 and CASP3+NKX3-1) were associated with the risk of developing PCa. Genotypes and tumor histopathological data indicated that the BCL-2, NKX3-1, and CASP3 allelic variants, either alone or combined in pairs, were associated with a poor prognosis of PCa. Conclusions Genetic polymorphisms in CASP3, NKX3-1, and BCL-2 genes were associated with susceptibility to PCa. The SNPs in the three genes alone and the SNP in the BCL-2 gene combined with the other two genes were strongly associated with adverse outcomes in PCa patients and are promising candidates for molecular markers for PCa prognosis.
- Open Access
- 22 January 2022
- Published by MDPI AG in Biomolecules
- Vol. 12 (2) , 187
MiR-182-5p Modulates Prostate Cancer Aggressive Phenotypes by Targeting EMT Associated Pathways
Prostate cancer (PCa) is a clinically heterogeneous disease, where deregulation of epigenetic events, such as miRNA expression alterations, are determinants for its development and progression. MiR-182-5p, a member of the miR-183 family, when overexpressed has been associated with PCa tumor progression and decreased patients’ survival rates. In this study, we determined the regulatory role of miR-182-5p in modulating aggressive tumor phenotypes in androgen-refractory PCa cell lines (PC3 and DU-145). The transient transfection of the cell lines with miR-182-5p inhibitor and mimic systems, significantly affected cell proliferation, adhesion, migration, and the viability of the cells to the chemotherapeutic agents, docetaxel, and abiraterone. It also affected the protein expression levels of the tumor progression marker pAKT. These changes, however, were differentially observed in the cell lines studied. A comprehensive biological and functional enrichment analysis and miRNA/mRNA interaction revealed its strong involvement in the epithelial-mesenchymal transition (EMT) process; expression analysis of EMT markers in the PCa transfected cells directly or indirectly modulated the analyzed tumor phenotypes. In conclusion, miR-182-5p differentially impacts tumorigenesis in androgen-refractory PCa cells, in a compatible oncomiR mode of action by targeting EMT-associated pathways.
- 22 January 2022
- Published by MDPI AG in Biomolecules
- Vol. 12 (2) , 187
Open AccessMiR-182-5p Modulates Prostate Cancer Aggressive Phenotypes by Targeting EMT Associated Pathways
Prostate cancer (PCa) is a clinically heterogeneous disease, where deregulation of epigenetic events, such as miRNA expression alterations, are determinants for its development and progression. MiR-182-5p, a member of the miR-183 family, when overexpressed has been associated with PCa tumor progression and decreased patients’ survival rates. In this study, we determined the regulatory role of miR-182-5p in modulating aggressive tumor phenotypes in androgen-refractory PCa cell lines (PC3 and DU-145). The transient transfection of the cell lines with miR-182-5p inhibitor and mimic systems, significantly affected cell proliferation, adhesion, migration, and the viability of the cells to the chemotherapeutic agents, docetaxel, and abiraterone. It also affected the protein expression levels of the tumor progression marker pAKT. These changes, however, were differentially observed in the cell lines studied. A comprehensive biological and functional enrichment analysis and miRNA/mRNA interaction revealed its strong involvement in the epithelial-mesenchymal transition (EMT) process; expression analysis of EMT markers in the PCa transfected cells directly or indirectly modulated the analyzed tumor phenotypes. In conclusion, miR-182-5p differentially impacts tumorigenesis in androgen-refractory PCa cells, in a compatible oncomiR mode of action by targeting EMT-associated pathways.
- Open Access
- 1 January 2020
- Published by FapUNIFESP (SciELO) in Genetics and Molecular Biology
- Vol. 43 (3) , e20180329
Association of polymorphisms of PTEN, AKT1, PI3K, AR, and AMACR genes in patients with prostate cancer
Polymorphic variants in the PTEN (rs2735343), PI3K (rs2699887), AKT1 (rs2494750), AR (rs17302090), and AMACR (rs3195676) genes were evaluated as possible molecular markers of susceptibility, prognosis, and progression of prostate cancer (PCa), in a case-control study. Samples consisted of 277 patients with PCa and 277 controls from Londrina, PR, Brazil. SNPs were analyzed by real-time PCR. A family history of cancer, including PCa, as well as level of schooling were risk factors for PCa. The data were obtained via logistic regression, using odds ratios with a CI 95%. The genotypes of AKT1 and AKT1+AR demonstrated an association with protection for the disease. The combination of SNPs with the histopathological tumor data between allele variants of AMACR, AKT1+AR, and AKT1+AMACR indicated an association with protection against seminal vesicle invasion. The polymorphisms AKT1+AR and PI3K+AR were associated with protection against tumor bilaterality. The genotype combinations PTEN+AMACR and PTEN+AR were associated with the risk of extracapsular extension. Of the five genes studied, two were associated with protection for PCa, four were associated with protection for some prognostic variables, and only one was associated with risk. Thus, these SNPs are candidates for markers to discriminate men with better or worse prognosis for PCa.
- 1 January 2020
- Published by FapUNIFESP (SciELO) in Genetics and Molecular Biology
- Vol. 43 (3) , e20180329
Open AccessAssociation of polymorphisms of PTEN, AKT1, PI3K, AR, and AMACR genes in patients with prostate cancer
Polymorphic variants in the PTEN (rs2735343), PI3K (rs2699887), AKT1 (rs2494750), AR (rs17302090), and AMACR (rs3195676) genes were evaluated as possible molecular markers of susceptibility, prognosis, and progression of prostate cancer (PCa), in a case-control study. Samples consisted of 277 patients with PCa and 277 controls from Londrina, PR, Brazil. SNPs were analyzed by real-time PCR. A family history of cancer, including PCa, as well as level of schooling were risk factors for PCa. The data were obtained via logistic regression, using odds ratios with a CI 95%. The genotypes of AKT1 and AKT1+AR demonstrated an association with protection for the disease. The combination of SNPs with the histopathological tumor data between allele variants of AMACR, AKT1+AR, and AKT1+AMACR indicated an association with protection against seminal vesicle invasion. The polymorphisms AKT1+AR and PI3K+AR were associated with protection against tumor bilaterality. The genotype combinations PTEN+AMACR and PTEN+AR were associated with the risk of extracapsular extension. Of the five genes studied, two were associated with protection for PCa, four were associated with protection for some prognostic variables, and only one was associated with risk. Thus, these SNPs are candidates for markers to discriminate men with better or worse prognosis for PCa.